Corrigendum: Urinary luteinizing hormone tests: which concentration threshold best predicts ovulation?
- 1Bruyère Continuing Care, Canada
- 2Department of Family Medicine, University of Ottawa, Canada
- 3Department of Family Medicine, University of Calgary, Canada
- 4Equipe Biostatistique- Sante, Laboratoire de Biometrie et Biologie Evolutive, Centre National de la Recherche Scientifique, Université de Lyon, France
Error in Figure/Table
In the original article, there was a mistake in ** Table 3. The Sensitivity (Se), Specificity (Sp), Positive Predictive value (PPV), Confidence Intervals (CI), Negative Predictive value (NNV) ,Likehood Ratios +’ve (LR+) and Likehood Ratios -’ve (LR-) for predicting ovulation within 24 hours at 15, 20, 25, 30, 35 and 40 mIU/ml thresholds on the 11th day of the cycle** as published. **Upon review of the tables prior to a journal club, it was noted that there were some numerical values that had been inadvertently misplaced under the wrong columns when updating different previously edited tables **. The corrected **Table 3** appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Ovulation Predictor Kits, Luteinizing Hormone, Natural family planning, Fertility awareness methods, Infertility, Urine, Ovulation, fertile window
Received: 31 Oct 2018;
Accepted: 07 Nov 2018.
Edited by:Rafael T. Mikolajczyk, Martin Luther University of Halle-Wittenberg, Germany
Copyright: © 2018 Leiva, Bouchard, ABDULLAH and Ecochard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Rene A. Leiva, Bruyère Continuing Care, Ottawa, Canada, email@example.com